XML 27 R9.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Operations | 9 Months Ended
--- | ---
Sep. 30, 2014
Operations [Abstract] |
Operations | Note 2 – Operations The Company's vaccine candidates currently under development, some of which may include an adjuvant, will require significant additional research and development efforts that include extensive pre-clinical and clinical testing, and regulatory approval prior to commercial use. As a clinical-stage biopharmaceutical company, the Company has primarily funded its operations from proceeds through the sale of its common stock in equity offerings and revenue under its contract with the Department of Health and Human Services, Biomedical Advanced Research and Development Authority (“HHS BARDA”) and, to a lesser degree, revenue under its contract with Path Vaccine Solutions (“PATH”). Management regularly reviews the Company's cash and cash equivalents and investments against its operating budget and forecast to monitor the sufficiency of the Company's working capital, and anticipates continuing to draw upon available sources of capital to meet its product development activities.

X
- Details
Name: | nvax_OperationsAbstract
Namespace Prefix: | nvax_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Operations Disclosure [Text Block] + References No definition available. + Details
Name: | nvax_OperationsDisclosureTextBlock
Namespace Prefix: | nvax_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration